Closed-loop neuromodulation promises high-fidelity control over mood at consumer scale. While clinical benefits are undeniable for severe affective disorders, ubiquitous affect regulation shifts mood from private experience to governed variable. We argue that this transition generates affective externalities—spillovers in creativity, empathy, dissent, and compliance—that conventional bioethics and health economics fail to price. We formalize a welfare model in which mood set-points are individually optimal but socially coupled through production, pro-sociality, and political legitimacy. We introduce the concept of affective conformity equilibria in which firms and platforms optimize output by narrowing variance around elevated hedonic baselines, producing a new pathology: Pathological Unhappiness—sorrow rendered deviant by design. We outline a preregistered experimental program (laboratory, field, and platform telemetry) to estimate causal effects of engineered happiness on creativity, moral judgment, and collective action; and we propose policy levers, from clinic consent to platform governance to labor law, that preserve therapeutic gains without erasing the cultural and civic functions of melancholy. The goal is not to romanticize suffering but to treat affect as shared infrastructure whose over-optimization erodes the social goods that sorrow sustains.
Joshua Luberisse (Fri,) studied this question.